$BDTX
Black Diamond Therapeutics Inc Stock $bdtx

$bdtx Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000170154120000032 Filed on November 10, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.430M	$5.550M	$2.520M
YoY Change	88.54%	120.24%	254.93%
% of Gross Profit
Research & Development	$17.76M	$12.93M	$5.634M
YoY Change	138.07%	129.48%	245.64%
% of Gross Profit
Depreciation & Amortization	$10.00K	$20.00K	$10.00K
YoY Change	0.0%	100.0%	0.0%
% of Gross Profit
Operating Expenses	$23.18M	$18.48M	$8.148M
YoY Change	124.12%	126.8%	248.35%
Operating Profit	-$23.18M	-$18.48M	-$8.148M
YoY Change	124.12%	126.8%	248.35%
Interest Expense	$1.250M	$0.00	$0.00
YoY Change	171.74%
% of Operating Profit
Other Income/Expense, Net	-$700.0K	$568.0K	-$1.120M
YoY Change	-7100.0%	-150.71%	5500.0%
Pretax Income	-$22.63M	-$17.91M	-$9.270M
YoY Change	129.05%	93.2%	292.8%
Income Tax
% Of Pretax Income
Net Earnings	-$22.63M	-$17.91M	-$9.268M
YoY Change	129.12%	93.27%	292.71%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.50
Diluted Earnings Per Share	-$627.7K	-$0.50	-$284.0K
COMMON SHARES
Basic Shares Outstanding	36.00M shares	35.93M shares
Diluted Shares Outstanding		35.93M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$315.1M	$333.1M	$78.70M
YoY Change	103.71%	323.22%
Cash & Equivalents	$34.61M	$56.20M	$78.66M
Short-Term Investments	$280.5M	$276.9M
Other Short-Term Assets	$4.500M	$3.400M	$300.0K
YoY Change	350.0%	1033.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$319.6M	$336.4M	$79.00M
YoY Change	105.22%	325.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$385.0K	$229.0K	$100.0K
YoY Change	134.76%	129.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$106.0K	$92.00K	$1.700M
YoY Change	79.66%	-94.59%
Total Long-Term Assets	$10.12M	$10.01M	$1.700M
YoY Change	291.94%	488.65%
TOTAL ASSETS
Total Short-Term Assets	$319.6M	$336.4M	$79.00M
Total Long-Term Assets	$10.12M	$10.01M	$1.700M
Total Assets	$329.7M	$346.4M	$80.70M
YoY Change	108.26%	329.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.538M	$2.932M	$1.400M
YoY Change	29.23%	109.43%
Accrued Expenses	$11.68M	$8.219M	$2.000M
YoY Change	302.9%	310.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.22M	$11.34M	$4.600M
YoY Change	192.37%	146.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.700M	$7.700M	$0.00
YoY Change
Total Long-Term Liabilities	$7.700M	$7.700M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.22M	$11.34M	$4.600M
Total Long-Term Liabilities	$7.700M	$7.700M	$0.00
Total Liabilities	$21.91M	$19.09M	$4.700M
YoY Change	349.11%	306.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$118.2M	-$95.60M
YoY Change	131.95%
Common Stock	$5.000K	$5.000K
YoY Change	400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$307.8M	$327.3M	-$39.79M
YoY Change
Total Liabilities & Shareholders Equity	$329.7M	$346.4M	$80.70M
YoY Change	108.26%	329.29%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$22.63M	-$17.91M	-$9.268M
YoY Change	129.12%	93.27%	292.71%
Depreciation, Depletion And Amortization	$10.00K	$20.00K	$10.00K
YoY Change	0.0%	100.0%	0.0%
Cash From Operating Activities	-$15.78M	-$11.48M	-$5.280M
YoY Change	110.12%	117.42%	183.87%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	$0.00	-$10.00K
YoY Change		-100.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	-$6.540M	$4.610M	-$30.00K
YoY Change		-15466.67%
Cash From Investing Activities	-$6.650M	$4.600M	-$30.00K
YoY Change	-33350.0%	-15433.33%	200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	830.0K	270.0K	44.33M
YoY Change	-99.01%	-99.39%	788.38%
NET CHANGE
Cash From Operating Activities	-15.78M	-11.48M	-5.280M
Cash From Investing Activities	-6.650M	4.600M	-30.00K
Cash From Financing Activities	830.0K	270.0K	44.33M
Net Change In Cash	-21.60M	-6.610M	39.02M
YoY Change	-128.42%	-116.94%	1150.64%
FREE CASH FLOW
Cash From Operating Activities	-$15.78M	-$11.48M	-$5.280M
Capital Expenditures	-$110.0K	$0.00	-$10.00K
Free Cash Flow	-$15.67M	-$11.48M	-$5.270M
YoY Change	108.66%	117.84%	184.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Entity Central Index Key EntityCentralIndexKey	0001701541
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38501
	dei	Entity Registrant Name EntityRegistrantName	BLACK DIAMOND THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-4254660
	dei	Entity Address Address Line1 EntityAddressAddressLine1	139 Main Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	City Area Code CityAreaCode	(617)
	dei	Local Phone Number LocalPhoneNumber	252-0848
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001
	dei	Trading Symbol TradingSymbol	BDTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35995660	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56197000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154666000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	276875000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3356000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1048000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	336428000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	155714000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	229000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	164000	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1223000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	55000	USD
CY2020Q3	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2019Q4	us-gaap	Deferred Costs DeferredCosts	2303000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8463000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	92000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	59000	USD
CY2020Q3	us-gaap	Assets Assets	346435000	USD
CY2019Q4	us-gaap	Assets Assets	158295000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2932000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1964000	USD
CY2020Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	190000	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8219000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2899000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11341000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4863000	USD
CY2020Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	16000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7749000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	19090000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	4879000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2020Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	200573000	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35963447	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35963447	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2236672	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2236672	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	422063000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3812000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	875000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95598000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50970000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	327345000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-47157000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	346435000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	158295000	USD
CY2020Q3	bdtx	Related Party Transaction Research And Development Expenses From Transactions With Related Party RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty	190000	USD
CY2019Q3	bdtx	Related Party Transaction Research And Development Expenses From Transactions With Related Party RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty	3480000	USD
	bdtx	Related Party Transaction Research And Development Expenses From Transactions With Related Party RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty	2293000	USD
	bdtx	Related Party Transaction Research And Development Expenses From Transactions With Related Party RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty	8497000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12929000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5634000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30453000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14293000	USD
CY2020Q3	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	0	USD
CY2019Q3	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	176000	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	0	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	357000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5551000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2514000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15934000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4695000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	18480000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	8148000	USD
	us-gaap	Operating Expenses OperatingExpenses	46387000	USD
	us-gaap	Operating Expenses OperatingExpenses	18988000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18480000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8148000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-46387000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18988000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	0	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	1000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1162000	USD
CY2019Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2787000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	21000	USD
CY2020Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2019Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1116000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-6416000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-594000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1027000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	568000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1120000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1759000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6395000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-17912000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-9268000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44628000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25383000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.50
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.42
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-12.36
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35927485	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	5295000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	875000	USD
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2065676	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31860716	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2054115	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-17912000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-9268000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44628000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25383000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-137000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	0	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18049000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9268000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43753000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25383000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44628000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25383000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1133000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-6416000	USD
	us-gaap	Depreciation Depreciation	37000	USD
	us-gaap	Depreciation Depreciation	38000	USD
	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	990000	USD
	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	0	USD
	bdtx	Rent Expense RentExpense	287000	USD
	bdtx	Rent Expense RentExpense	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2308000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	270000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	33000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	25000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1528000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	496000	USD
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	190000	USD
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-453000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4551000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	860000	USD
	bdtx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-301000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36372000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17188000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	17765000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	292775000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-275043000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	44669000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	270000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1275000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	213844000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	408000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	214114000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44261000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-97301000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27054000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154721000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51660000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57420000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78714000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56197000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78659000	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1223000	USD
CY2019Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	55000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57420000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78714000	USD
	bdtx	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	USD
	bdtx	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	1169000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	200573000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	8274000	USD
	us-gaap	Line Of Credit Assumed1 LineOfCreditAssumed1	1168000	USD
	us-gaap	Line Of Credit Assumed1 LineOfCreditAssumed1	0	USD
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	33668075	shares
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	60770000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-15542000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	91000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3828000	USD
CY2019Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	33668075	shares
CY2019Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	60770000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-19279000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	192000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-12287000	USD
CY2019Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	33668075	shares
CY2019Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	60770000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-31374000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	850000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-9268000	USD
CY2019Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	45419229	shares
CY2019Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	115840000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	-39792000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	64839353	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	200573000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-47157000	USD
CY2020Q1	bdtx	Reclassifications Of Temporary To Permanent Equity Shares ReclassificationsOfTemporaryToPermanentEquityShares	64839353	shares
CY2020Q1	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	200573000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	200573000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	212101000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	16000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1877000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12145000	USD
CY2020Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	355265000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1419000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	1012000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-14571000	USD
CY2020Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	343125000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	270000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	3.01581
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1999000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-137000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-17912000	USD
CY2020Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	327345000	USD
	us-gaap	Use Of Estimates UseOfEstimates	Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
CY2019Q4	us-gaap	Deferred Costs DeferredCosts	2303000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	16000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	16000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	276000000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	875000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	276875000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	378000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	276000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	149000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	112000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	229000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	164000	USD
	us-gaap	Depreciation Depreciation	37000	USD
	us-gaap	Depreciation Depreciation	38000	USD
CY2020Q3	bdtx	Accrued Contract Research Service Fees Current AccruedContractResearchServiceFeesCurrent	1088000	USD
CY2019Q4	bdtx	Accrued Contract Research Service Fees Current AccruedContractResearchServiceFeesCurrent	434000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2733000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1182000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3141000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	984000	USD
CY2020Q3	bdtx	Accrued Legal Fees Current AccruedLegalFeesCurrent	320000	USD
CY2019Q4	bdtx	Accrued Legal Fees Current AccruedLegalFeesCurrent	299000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	937000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8219000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2899000	USD
CY2020Q1	bdtx	Shares Authorized SharesAuthorized	510000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1999000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	850000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5295000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1133000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1351593	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2043000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3639228	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	39763	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	51076	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.47
CY2020Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	26283000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-17912000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-9268000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44628000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25383000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35927485	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2065676	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31860716	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2054115	shares
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.50
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.42
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-12.36
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3698562	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16805011	shares
	bdtx	Lessee Operating Lease Number Of Contracts LesseeOperatingLeaseNumberOfContracts	2	contract
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	274000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	386000	USD
CY2020Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	211000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	476000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	9000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	31000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	494000	USD
	us-gaap	Lease Cost LeaseCost	893000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	167000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	266000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1485000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1351000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1306000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1339000	USD
CY2020Q3	bdtx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	4829000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10576000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1891000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	8685000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	223000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	228000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	77000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	528000	USD
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2020Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	161000	USD
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	428000	USD
CY2019Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	64000	USD
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	125000	USD
CY2020Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	190000	USD
CY2019Q4	bdtx	Prepaid Expense Related Party Current PrepaidExpenseRelatedPartyCurrent	916000	USD
CY2020Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	190000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	2293000	USD
CY2019Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	3656000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	8854000	USD

Files In Submission

Name	View Source	Status
0001701541-20-000032-index-headers.html	Edgar Link	pending
0001701541-20-000032-index.html	Edgar Link	pending
0001701541-20-000032.txt	Edgar Link	pending
0001701541-20-000032-xbrl.zip	Edgar Link	pending
bdtx-20200930.htm	Edgar Link	pending
bdtx-20200930.xsd	Edgar Link	pending
bdtx-20200930_cal.xml	Edgar Link	unprocessable
bdtx-20200930_def.xml	Edgar Link	unprocessable
bdtx-20200930_htm.xml	Edgar Link	completed
bdtx-20200930_lab.xml	Edgar Link	unprocessable
bdtx-20200930_pre.xml	Edgar Link	unprocessable
exhibit311q32020.htm	Edgar Link	pending
exhibit312q32020.htm	Edgar Link	pending
exhibit321q32020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BDTX
Black Diamond Therapeutics Inc Stock $bdtx

2020 Q4 Form 10-Q Financial Statement

#000170154120000032 Filed on November 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDTX Black Diamond Therapeutics Inc Stock $bdtx

2020 Q4 Form 10-Q Financial Statement

#000170154120000032 Filed on November 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDTX
Black Diamond Therapeutics Inc Stock $bdtx